"Exploiting ASS1 deficiency in the treatment of mesothelioma"

Add to your list(s) Download to your calendar using vCal

• Dr Peter Szlosarek, Cancer Research UK Clinician Scientist, Senior Lecturer and Honorary Consultant in Medical Oncology, Barts and The London
• Tuesday 27 March 2012, 11:30-13:00
• Seminar Room 2, Clinical School, Addenbrooke’s.

If you have a question about this talk, please contact Mala Jayasundera.

Malignant pleural mesothelioma is an intractable asbestos-related cancer with a median survival of less than 12 months and an estimated total economic burden running into several billion pounds. We have identified epigenetic loss of the rate-limiting enzyme for arginine synthesis argininosuccinate synthetase (ASS1) in mesothelioma cells revealing a novel Achilles’ heel using arginine deprivation. A CRUK -funded randomized phase 2 trial of the arginine-depleting agent ADI -PEG20 and best supportive care (Polaris Group, US) versus best supportive care alone is underway in patients with ASS1 -deficient mesothelioma in the UK. Current preclinical and clinical work will be discussed with an emphasis on developing arginine deprivation as a novel therapeutic option for patients with mesothelioma and other ASS1 -deficient cancers.

This talk is part of the Cambridge Oncology Seminar Series series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biology
• CCC talks for website
• CRUK CI Seminars
• Cambridge Oncology Seminar Series
• Life Sciences
• Life Sciences
• ME Seminar
• MRC Cancer Unit Seminars
• PMRFPS's
• Seminar Room 2, Clinical School, Addenbrooke’s
• cancer
• cri
• my_list
• other talks
• se393's list
• sfm36

Note that ex-directory lists are not shown.